

What is claimed is:

1. A biocompatible therapeutic article comprising, a macromer, a polypeptide, and a molecule or mixture of molecules which preferentially excludes proteins, wherein said polypeptide is insoluble in said article, wherein  
5 said polypeptide is selected from parathyroid-related polypeptide, somatostatin, luteinizing hormone releasing hormone, GLP-1 amylin and GLP-1 amyline analogues.
2. The biocompatible therapeutic article of claim 1, wherein said molecule which preferentially excludes proteins is selected from the group consisting of a  
10 macromer, poly(ethylene glycol), hyaluronic acid, and poly(vinylpyrrolidone).
3. The biocompatible therapeutic article of claim 1, wherein said macromer comprises:
  - (a) a region forming a central core;
  - (b) at least two degradable regions attached to said core; and
  - 15 (c) at least two polymerizable end groups, wherein said polymerizable end groups are attached to said degradable regions.
4. The biocompatible therapeutic article of claim 3, wherein said central core comprises a polymer selected from the group consisting of poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(vinylpyrrolidone),  
20 poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers, polysaccharides, carbohydrates, proteins, and combinations thereof.

5. The biocompatible therapeutic article of claim 3, wherein said degradable regions comprise a polymer selected from the group consisting of poly( $\alpha$ -hydroxy acids), poly(lactones), poly(amino acids), poly(anhydrides), poly(orthoesters), poly(orthocarbonates), and poly(phosphoesters).

5           6. The biocompatible therapeutic article of claim 1, wherein said polypeptide is parathyroid-related polypeptide.

7. The biocompatible therapeutic article of claim 1, wherein said polypeptide is somatostatin.

8. The biocompatible therapeutic article of claim 1, wherein said  
10 polypeptide is luteinizing hormone releasing hormone.

9. The biocompatible therapeutic article of claim 1, wherein said polypeptide is GLP-1 amylin or GLP-1 amyline analogues.

10. The biocompatible therapeutic article of claim 1, wherein said article comprises at least 5% polypeptide by dry weight.